摘要
1例83岁男性患者使用表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)药物阿法替尼(30 mg,qd,po)治疗晚期肺腺癌。用药后第7天,患者突发胸闷气急,听诊双下肺可闻及爆裂音,动脉血气分析SO292.8%,胸部CT可见双肺新发磨玻璃影,双肺间质性病变较前进展。立即停用阿法替尼,予甲泼尼龙琥珀酸钠(40 mg,q 12 h,ivgtt)抗炎治疗、氧疗联合辅助抗感染、抗纤维化等对症积极治疗,但患者病情持续进展,最终多脏器功能衰竭,治疗无效。
One 83-year-old male patient was treated with afatinib(30 mg,qd,po),a kind of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI),for advanced lung adenocarcinoma.7 days later,the patient developed chest distress and shortness of breath with burst in double low lung.Arterial blood gas analysis showed that the oxygen saturation(SO2)was 92.8%.And new ground glass shadow in both lungs could be seen on chest CT,which indicated that his interstitial lung disease aggravated.Afatinib was stopped immediately and methylprednisolone sodium succinate(40 mg,q 12 h,ivgtt)for anti-inflammatory,oxygen therapy,and auxiliary treatments including anti-infection,anti-fibrosis,etc were given to him.But the patient's condition continued to deteriorate due to multiple organ failure.
作者
冯瑾
恽芸蕾
侯幸赟
FENG Jin;YUN Yun-lei;HOU Xing-yun(Department of Pharmacy,Shanghai Changzheng Hospital,Shanghai 200001,China)
出处
《中国药物应用与监测》
CAS
2020年第4期276-278,共3页
Chinese Journal of Drug Application and Monitoring
基金
上海市卫生计生系统重要薄弱学科建设项目(2016ZB0303)。
